PARP1’s hidden repair job: opening packed DNA
PARP1
An enzyme that senses DNA damage and helps start repair.
nucleosome
A compact structure made from DNA wrapped around histone proteins.
hexasome
A partly open nucleosome with six histone proteins.
What happened
Researchers at St. Jude Children's Research Hospital found a new job for PARP1, an enzyme involved in DNA repair. Their results were published in Molecular Cell. When DNA is damaged, PARP1 does more than detect the problem and send a repair signal. It can also directly loosen the DNA packaging near the damage. That opening may help other repair proteins reach the site.
Why the packaging matters
DNA is very long. In the nucleus, it is wrapped around histone proteins. Eight histones form the core of a nucleosome, a compact unit of chromatin. This arrangement helps fit DNA inside a cell. It also creates a barrier. Repair machinery cannot work efficiently if the damaged DNA stays hidden inside a tight package. Scientists already knew that PARP1 senses DNA damage and uses a chemical signal called poly(ADP-ribosyl)ation. They did not know exactly how PARP1 overcame the nucleosome barrier.
The mechanism the team found
The St. Jude team combined biochemical tests with tests in cells. They found that PARP1 asymmetrically removes two histone proteins next to the damaged DNA. The remaining six histones form a partly open structure called a hexasome. This is not simply a broken package. The modified structure can help gather proteins at the damage site and support repair. The researchers also identified an important control point: the C-terminal tail of histone H2A. This tail can contain mutations associated with cancer. Removing it made cells more sensitive to DNA-damaging treatments and to PARP inhibitors.
Why it matters for cancer treatment
The result may change how scientists think about PARP-targeting drugs. Current PARP inhibitors broadly block PARP catalytic activity. In doing so, they can shut down many PARP functions, which may create toxic effects. The new finding separates one possible function from the others. A future treatment might block PARP1’s remodeling activity in cells that depend on it. Such a strategy could be more selective. However, the study does not show that this approach is already safe or effective in people.
What is established—and what is not
The experiments support a direct role for PARP1 in disassembling nucleosomes near DNA damage. They also connect the H2A tail with this process and with cellular sensitivity to DNA-damaging treatments. These are mechanistic findings. They are not results from a patient trial. The report does not establish which cancers would benefit, how a drug would target remodeling alone, or whether that approach would reduce side effects.
What to watch next
The next step is to test whether scientists can separate PARP1’s repair-opening activity from its other activities. They will also need to learn how different H2A changes affect the response. If the mechanism can be targeted precisely, it could provide a route toward more focused cancer therapy. For now, the important news is the discovery of a cellular process, not a finished medicine.
Scientists find another way PARP1 helps repair DNA
📰 Full story: PARP1’s hidden repair job: opening packed DNA
PARP1 helps cells find DNA damage. It can also open the DNA package near that damage. This may help scientists design more focused cancer drugs.
PARP1
An enzyme that detects DNA damage and helps begin repair.
nucleosome
A compact DNA package made with histone proteins.
hexasome
A partly open structure with six histone proteins.
💡 The gist
- PARP1 helps cells notice damaged DNA.
- It can also open the DNA package near the damage.
- This may guide more focused cancer treatments.
DNA carries instructions for building and running a cell. It is very long, so cells pack it tightly. DNA wraps around histone proteins. Together, they form a nucleosome. A nucleosome is a compact DNA package. Eight histones help make its core.
Packing saves space. It can also hide damaged DNA. Repair proteins must reach the damaged spot. PARP1 was already known as an early responder. It senses damage and sends signals that begin repair.
Researchers at St. Jude Children’s Research Hospital, a medical research center, studied what happens next. They used biochemical tests and tests in cells. They found that PARP1 removes two nearby histones. That leaves six histones in a partly open structure. Scientists call this structure a hexasome.
The hexasome is not simply a broken package. It creates a more accessible area near the damage. Repair proteins can gather there and begin their work. This explains one physical step between damage detection and repair.
The team also studied a tail-like end of histone H2A. Removing that end made cells more sensitive to DNA-damaging treatments. It also increased sensitivity to PARP inhibitors. The H2A tail appears to help control how well PARP1 opens the package.
Why might this matter for cancer? Some cancers have weaknesses in DNA repair. Blocking repair can harm those cells more. Current PARP inhibitors broadly block PARP catalytic activity. Researchers say this broad action can cause toxic effects. One drug may affect several PARP functions at once.
The new finding points to another strategy. A future drug might block only PARP1’s remodeling job. That could make treatment more selective. However, this is only a research possibility. The study did not test a new drug in patients. Scientists still need to identify useful cancer targets, test safety, and measure real treatment benefits. For now, the discovery gives them a clearer process to investigate.
PARP1 helps open hurt DNA
📰 Full story: PARP1’s hidden repair job: opening packed DNA
PARP1 is a tiny cell helper that notices damaged DNA.
PARP1
A cell helper that notices damaged DNA.
DNA is like a book of body instructions. It is packed inside each cell. Sometimes a page gets hurt. The cell needs to fix it.
PARP1 is a helper with a special job. It notices the hurt place. Then it moves some packing pieces aside. The repair helpers can reach the DNA more easily.
Scientists found this while studying cells. The finding may help make cancer medicines more exact. But it is not a ready medicine. More work is needed before doctors can use it.